Sacituzumab Govitecan
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Sacituzumab Govitecan
- Sacituzumab govitecan: From an Unspecified Approved Indication to Drug-Induced Osteoporosis
Sacituzumab govitecan: From an Unspecified Approved Indication to Drug-Induced Osteoporosis
One-Sentence Summary
Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate carrying a topoisomerase I inhibitor payload (SN-38), and it is marketed in Singapore as Trodelvy. The TxGNN model predicts it may be effective for drug-induced osteoporosis, but 0 clinical trials and 0 publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the registration data compiled for this report |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge of the drug class, sacituzumab govitecan is an antibody-drug conjugate. The antibody part targets Trop-2 on tumour cells and delivers SN-38, a topoisomerase I inhibitor, which is a cytotoxic mechanism.
This prediction is hard to justify mechanistically. No plausible link connects a cytotoxic, tumour-targeted agent to bone-protective effects. Cytotoxic chemotherapy and its supportive care, such as myelosuppression, gastrointestinal toxicity and steroid co-medication, are more likely to harm bone health than to treat bone loss. The high TxGNN score most likely reflects knowledge-graph artefacts rather than real biology.
The other top-ranked predictions are diabetic retinopathy (including severe non-proliferative disease) and several cataract types. They show the same pattern: all are Evidence Level L5, with no trials or literature, and no recognised mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16425P | TRODELVY POWDER FOR SOLUTION FOR INFUSION 180 MG/VIAL | Injection, powder, lyophilised, for solution | Not listed in the data compiled for this report |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antibody-drug conjugate with a cytotoxic topoisomerase I inhibitor payload (SN-38, the active metabolite of irinotecan) |
| Myelosuppression Risk | High (neutropenia is an expected toxicity of this class); please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | CBC with differential, liver and renal function, and monitoring for diarrhoea and hypersensitivity reactions |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Drug Interactions: 40 interactions were identified. Those listed below are examples from the first 20 returned.
- Major: deferiprone, fostamatinib, adalimumab, apalutamide, certolizumab pegol, cladribine, dacomitinib, irinotecan, leflunomide, natalizumab, nilotinib, ozanimod
- Moderate: alefacept, alemtuzumab, anakinra, canakinumab, dimethyl fumarate, lorlatinib, ocrelizumab, omacetaxine mepesuccinate
- Many of these are immunosuppressive or myelosuppressive agents, so overlapping toxicity is a concern. Irinotecan shares the SN-38 active metabolite.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (Evidence Level L5). There are no trials or publications, and no credible mechanism links a cytotoxic Trop-2-directed ADC to drug-induced osteoporosis. The systemic toxicity of this drug is also disproportionate to the proposed use, and chemotherapy tends to worsen bone health.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, and the approved indication text for the Singapore licence
- Mechanism of action data
- Any preclinical or clinical evidence linking the drug to bone metabolism
- A risk-benefit assessment against established osteoporosis therapies
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.